Manava Plus

Manava Plus operates at the intersection of biotechnology, neuroscience, medical devices, and software. Its stated focus is a living neuroprosthesis that combines patient-derived neural organoids with bioelectronics and AI, aiming to create a biological pathway through neural injury rather than simply bypassing it. Manava Plus is a private, early-stage company founded in March 2022, with an indicated team size of 1–10 employees. Its reported €7.5 million in non-dilutive grants and preclinical technical milestones suggest a research-led position, while clinical validation, regulatory progress, and product commercialization remain important unknowns.

Founded in March 2022, Manava Plus remains a small private company, with an indicated employee range of 1–10. Its development path is centered on bringing together patient-derived neural organoids, bioengineered structures, implantable hardware, and AI-driven signal processing. The milestones described—biocompatibility validation of functional hardware prototypes, implantation of living human neural organoids in animal models, and an AI engine trained on data from more than 250 human organoids—show activity across several technical workstreams. The company also reports securing €7.5 million in non-dilutive government grants, which provides evidence of grant support but is not a disclosed equity funding round. With no disclosed hiring news, financing history, or clinical timeline, the pace and resourcing of future development cannot be reliably projected.